IRINA SHCHEDROV
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner AUBURN, CA NPI 1669067013
Browse related groups: Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner CA Gilead Sciences, Inc. All categories
General Payments — all program years on this page
$2,080.51
- Category: General Payments
- Program years: PY2021–2024
- Record count: 19
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $953.52 across 8 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $953.52 | 8 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| Gilead Sciences, Inc. | $227.14 | 2 |
| Acerta Pharma LLC | $143.46 | 1 |
| Teva Pharmaceuticals USA, Inc. | $124.82 | 1 |
| Alnylam Pharmaceuticals Inc. | $121.86 | 1 |
| Shionogi Inc | $120.46 | 1 |
| MAYNE PHARMA COMMERCIAL LLC | $119.93 | 1 |
| Janssen Pharmaceuticals, Inc | $95.85 | 1 |
By program year
Records — PY2024 (8)
| Record ID | Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Source |
|---|---|---|---|---|---|---|---|
| 1077937682 | Janssen Pharmaceuticals, Inc | $95.85 | 11/12/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1105832787 | AstraZeneca Pharmaceuticals LP | $143.46 | 08/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1125840893 | Alnylam Pharmaceuticals Inc. | $121.86 | 01/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133656636 | Gilead Sciences, Inc. | $114.53 | 07/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1133656638 | Gilead Sciences, Inc. | $112.61 | 09/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1151613668 | Teva Pharmaceuticals USA, Inc. | $124.82 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1154336006 | Shionogi Inc | $120.46 | 11/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
| 1154759998 | MAYNE PHARMA COMMERCIAL LLC | $119.93 | 02/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | View at CMS |
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.